Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion

Fineline Cube Feb 28, 2026
Company Drug

Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA

Fineline Cube Feb 28, 2026
Policy / Regulatory

National VBP Tender Program Invites Drugs Approved Before October 30 for Round 9

Fineline Cube Oct 23, 2023

The National Allied Procurement Office has released a notification regarding Round 9 of the national...

Company Deals

MSD Cancels Development of Two Pre-Clinical ADCs from Sichuan Kelun-Biotech

Fineline Cube Oct 23, 2023

China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) and its innovative drug development subsidiary Sichuan...

Company Drug

Health Canada Approves Pfizer and Sumitomo Pharma’s Myfembree for Endometriosis Pain Management

Fineline Cube Oct 23, 2023

Health Canada has granted regulatory approval to Pfizer (NYSE: PFE) and Sumitomo Pharma (TYO: 4506)...

Company

Shanghai Henlius Receives GMP Certification from ANVISA for Biosimilar Manufacturing

Fineline Cube Oct 23, 2023

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Henlius Biotech,...

Company Drug

Shanghai Fudan-Zhangjiang’s ADC FZ-AD005 Accepted for NMPA Review in Advanced Solid Tumors

Fineline Cube Oct 23, 2023

China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505) has announced that the National...

Company Deals

AcuVu Medical Partners with Hologic for US Distribution of HummingScope Hysteroscopy System

Fineline Cube Oct 23, 2023

AcuVu Medical, a specialist in electronic endoscopes with operations in California, USA, and Suzhou, China,...

Company Deals

CBC HIP Secures USD 875 Million for Life Science Real Assets Venture CLSRA

Fineline Cube Oct 23, 2023

CBC Healthcare Infrastructure Platform (CBC HIP), a prominent independent life science real assets investor in...

Company Drug

BeiGene’s Brukinsa Gains NICE Recommendation for CLL Treatment in the UK

Fineline Cube Oct 23, 2023

China-based biotech BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced that the National...

Company Drug

Jacobio Pharma’s Glecirasib Combo Shows Promising Results in ESMO Congress 2023 Presentation

Fineline Cube Oct 23, 2023

China-based Jacobio Pharma (HKG: 1167) has presented clinical data for its KRAS G12C inhibitor glecirasib...

Company Deals

Hotgen Biotech Partners with Genoval Therapeutics for RNAi Drug Development

Fineline Cube Oct 23, 2023

China’s Hotgen Biotech Co., Ltd (SHA: 688068) has announced a strategic partnership between its anti-aging...

Company Deals

Hansoh Pharmaceutical and GSK Ink Global Licensing Deal for Innovative ADC HS-20089

Fineline Cube Oct 23, 2023

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has entered into a licensing agreement with...

Company Drug

InxMed Presents Positive Data for FAK Inhibitor Ifebemtinib at ESMO 2023

Fineline Cube Oct 23, 2023

China-based firm InxMed (Nanjing) Co., Ltd has updated two clinical studies for its first-in-class small-molecule...

Company Deals

Foundation Medicine Expands Genomic Profiling Partnership with Sequanta Technologies in China

Fineline Cube Oct 23, 2023

US-based Contract Research Organization (CRO) Foundation Medicine Inc. has announced the expansion of its existing...

Company Medical Device

Jenscare’s LuX-Valve Plus Completes Compassionate Use Cases in Asia-Pacific

Fineline Cube Oct 20, 2023

Jenscare Scientific Co., Ltd (HKG: 9877), a leading device maker specializing in structural heart disease...

Company Deals

Fosun Pharmaceutical to Acquire 14% Stake in UnitedHealthcare for USD 34 Million

Fineline Cube Oct 20, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced plans to invest RMB 248.9...

Company Drug

Beijing SL Pharmaceutical Gains NMPA Approval for Phase I Trial of MBT-1608 for Hepatitis C

Fineline Cube Oct 20, 2023

China’s Beijing SL Pharmaceutical Co., Ltd (SHE: 002038) has announced that it has received approval...

Company Drug

Skyline Therapeutics Gains NMPA Approval for SKG0106 in Neovascular AMD Treatment

Fineline Cube Oct 20, 2023

Skyline Therapeutics has announced that it has received clinical trial approval from the National Medical...

Company Drug

Accuredit Therapeutics Initiates First Dosing of Gene Therapy ART001 for ATTR

Fineline Cube Oct 20, 2023

China-based gene therapy start-up Accuredit Therapeutics (Suzhou) Co., Ltd has announced the first dosing of...

Company

Bayer HealthCare Launches First Innovation Center in Beijing’s ETown

Fineline Cube Oct 20, 2023

Bayer HealthCare (ETR: BAYN) has formally inaugurated its inaugural innovation center in China, strategically situated...

Legal / IP Policy / Regulatory

China’s State Council Unveils Plan to Boost Patent Commercialization by 2025

Fineline Cube Oct 20, 2023

China’s State Council has recently approved the “Special Action Plan for Patent Commercialization and Utilization...

Posts pagination

1 … 418 419 420 … 628

Recent updates

  • Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion
  • Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA
  • Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer
  • Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis
  • Dupixent Wins CHMP Positive Opinion for Pediatric CSU – EU Approval Nears for Children Aged 2–11 Years
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Dupixent Wins Two NMPA Approvals in China – First Biologic for Bullous Pemphigoid and Pediatric Asthma Expansion

Company Drug

Olumiant Wins CHMP Positive Opinion for Pediatric Alopecia – JAK Inhibitor Nears EU Approval for Teens with Severe AA

Company Drug

Henlius’ HLX11 Wins CHMP Positive Opinion – Perjeta Biosimilar Nears EU Approval for HER2+ Breast Cancer

Company Drug

Shionogi Files CORECTIM Lotion for Japan Approval – Expands Topical JAK Inhibitor Franchise in Atopic Dermatitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.